BCR and B-cell chronic lymphocytic leukemia: Furthermore, therapy with BCR axis inhibitors such as ibrutinib111, acalabrutinib69, idelalisib124, and duvelisib116 results in a decline in MCL-1 protein levels in CLL cells, providing a mechanism-based rationale to combine them with venetoclax.